Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Atea Pharmaceuticals, Inc.

< Previous 1 2 Next >
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir Combination
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals’ Board of Directors Unanimously Rejects Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra Biosciences
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals Confirms Receipt of Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra Biosciences
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call on May 8, 2023
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to Bemnifosbuvir, an Investigational Oral Antiviral, for the Treatment of COVID-19
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Announces Presentation of Bemnifosbuvir Data Demonstrating Reduced Hospitalizations for COVID-19 Patients at 2023 European Congress of Clinical Microbiology & Infectious Diseases
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C Presented at 2023 International Conference on Antiviral Research
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C to be Presented at 2023 International Conference on Antiviral Research
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals Presents Favorable Drug Interaction Profile of Bemnifosbuvir in Phase 1 Studies at CROI 2023
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals to Present Data on Bemnifosbuvir Drug Interaction Profile at Conference on Retroviruses and Opportunistic Infections
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals Highlights Strategic Priorities for 2023
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.